Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (CYCN) is a Nasdaq-listed clinical-stage biopharmaceutical company that provides frequent updates on its progress in neuropsychiatric drug development and the monetization of its legacy soluble guanylate cyclase (sGC) portfolio. This news page aggregates company press releases and market-moving announcements so readers can follow how Cyclerion’s strategy and pipeline evolve over time.
Recent news highlights Cyclerion’s transformation into a neuropsychiatric company, centered on an individualized therapy for treatment-resistant depression (TRD). The company has reported a license agreement with the Massachusetts Institute of Technology for technology to treat neuropsychiatric disorders and has announced CYC-126, an anesthetic-based investigational therapy that uses real-time EEG monitoring and algorithm-guided dosing, as its lead program for TRD.
Investors and observers can also track Cyclerion’s collaboration and business development activity. Updates include an application-specific, exclusive collaboration with Medsteer SAS to integrate closed-loop anesthetic delivery technology into CYC-126, as well as agreements to sell or license legacy sGC assets such as zagociguat, CY3018, praliciguat, and olinciguat. These items illustrate how the company aims to generate non-dilutive funding while building its neuropsychiatric pipeline.
In addition, the news flow covers corporate governance and capital markets developments, including board appointments, leadership changes, reverse stock split actions, and Nasdaq listing compliance updates. By reviewing this page regularly, readers can follow Cyclerion’s clinical plans, partnership announcements, licensing milestones, and strategic updates that may influence the CYCN stock narrative.
Cyclerion Therapeutics (Nasdaq: CYCN) announced the formation of clinical and scientific advisory boards to advance its therapeutic pipeline, particularly focusing on CY6463, a CNS-penetrant sGC stimulator targeting cognitive impairment. The new advisory boards consist of prominent experts in CNS diseases and therapeutic development, with a goal to optimize the company's development path. CY6463 is currently under clinical investigation for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS).
Cyclerion Therapeutics (Nasdaq: CYCN) announced its participation in two upcoming investor conferences. The company will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. ET, with a webcast available on their website. Additionally, an on-demand presentation will be available at the H.C. Wainwright BioConnect Conference on January 11, 2021, at 6:00 a.m. ET. Cyclerion focuses on innovative treatments for serious CNS diseases, notably their lead program, CY6463, aimed at conditions like MELAS and Alzheimer's with vascular pathology.
Cyclerion Therapeutics (Nasdaq: CYCN) announced key executive promotions effective January 1, 2021. Anjeza Gjino has been promoted to Chief Financial Officer, succeeding Bill Huyett, who will transition to a part-time Strategic Advisor role. Cheryl Gault is elevated to Chief Operating Officer. Amy Schulman is stepping down from the Board of Directors. Both Gjino and Gault have extensive backgrounds, with Gjino previously leading finance at Ironwood Pharmaceuticals and Gault having significant corporate strategy experience. These changes are expected to strengthen leadership and strategic direction at Cyclerion.
Cyclerion Therapeutics (Nasdaq: CYCN) announced positive results from its IW-6463 pharmacology study, showing significant benefits for age-related cognitive decline. The company plans to focus on its IW-6463 CNS program, with a projected 50% reduction in cash use for 2021 from Q3 2020 levels. Currently, cash reserves stand at approximately $71 million, expected to fund CNS priorities, including upcoming studies for MELAS and Alzheimer's disease. Despite impressive data, Cyclerion’s sickle cell program faced challenges, with inadequate activity results from the STRONG-SCD study.
Cyclerion Therapeutics (CYCN) announced promising Phase 1 study results for IW-6463, a soluble guanylate cyclase stimulator, demonstrating significant improvements in neurophysiological measures related to cognitive decline and neurodegenerative diseases. The study confirmed blood-brain-barrier penetration and a favorable safety profile. Cyclerion plans to initiate Phase 2 trials for Mitochondrial Encephalomyopathy and Alzheimer's disease in 2021, supported by a $2 million grant from the Alzheimer's Association. The company's commitment to addressing serious CNS diseases remains strong.
Cyclerion Therapeutics (Nasdaq: CYCN) announced that the results from its STRONG-SCD study of olinciguat, an investigational treatment for sickle cell disease, do not support further development. While olinciguat was generally well tolerated, the data revealed insufficient activity for continued clinical progression. The company plans to analyze the findings and explore potential partnerships for the program. Cyclerion will pivot its focus towards serious central nervous system diseases, particularly its lead program, IW-6463.
Cyclerion Therapeutics (Nasdaq: CYCN), a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in September 2020. Key events include the Citi’s 15th Annual BioPharma Virtual Conference on September 9th, H.C. Wainwright's 22nd Annual Global Investment Conference on September 16th, and the Cantor Virtual Global Healthcare Conference on September 16th and 17th. Additionally, Cyclerion will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21st. Webcasts of presentations will be accessible via Cyclerion's website for 90 days.
Cyclerion Therapeutics (Nasdaq: CYCN) announced it received a $2 million grant from the Alzheimer's Association to support its Phase 2 trial of IW-6463 for Alzheimer's Disease with vascular pathology (ADv). The funding will be dispensed over two years, enhancing the company's research efforts into the treatment potential of IW-6463, a CNS-penetrant soluble guanylate cyclase stimulator. Topline data from a related pharmacology study in elderly participants is expected in September 2020, underscoring the company's commitment to addressing cognitive symptoms in dementia.
Cyclerion Therapeutics (CYCN) announced key updates including the expected late summer results for IW-6463 and olinciguat clinical studies. The company completed a $24 million private equity placement to boost IW-6463's development for CNS diseases, including MELAS and Alzheimer's, and olinciguat for sickle cell disease. Revenue for Q2 2020 stood at $0.7 million, down from $1.6 million the previous year, while net loss decreased to $20 million from $32 million. Cyclerion aims to tackle serious CNS diseases and sickle cell disease with innovative therapies.
Cyclerion Therapeutics (CYCN) announced the presentation of IW-6463 at the Annual Biomarkers in Alzheimer’s Disease Summit on July 15, 2020. IW-6463, targeting Alzheimer’s disease with vascular pathology, has shown positive outcomes in preclinical studies across cerebral blood flow, cellular bioenergetics, neuro-inflammation, and neuronal function. The company is preparing for clinical pharmacology trials later this summer. Dr. Chris Wright highlighted the potential of IW-6463 to improve patient outcomes in neurodegenerative diseases, addressing a significant unmet need.